#esmo22 highlights on pembrolizumab with crt in locally advanced hnscc: the keynote-412 study
Published 1 year ago • 885 plays • Length 2:17Download video MP4
Download video MP3
Similar videos
-
2:57
keynote-412: pembrolizumab with crt vs placebo plus crt for locally advanced hnscc
-
2:22
#esmo22 highlights on neoadj. vs adjuvant pembrolizumab in resected stage iii-iv melanoma:swog s1801
-
3:11
esmo 2020 highlights on pembrolizumab in la-hnscc: the gortec 2015-01 “pembrorad” study
-
3:16
#esmo22 highlights on tils versus ipilimumab in patients with advanced melanoma: the phase 3 study
-
2:30
#esmo22 highlights on first-line atezolizumab in nsclc not eligible for platinum: the ipsos study
-
2:46
#esmo22 highlights on neoadjuvant ici in locally advanced dmmr colon cancer: the niche-2 study
-
1:52
esmo 2022 highlights in head and neck cancer
-
3:21
esmo 2020 highlights on pembrolizumab as 1st line therapy for auc: the keynote-361 study
-
2:56
#esmo22 highlights on nirogacestat in patients with progressing desmoid tumours: the defi study
-
3:35
#esmo22 highlights on actionable inflammatory axis for air pollution induced nsclc
-
2:19
#esmo21 highlights on pembrolizumab in fully resected high-risk stage ii melanoma: keynote-716 study
-
3:15
highlights on pembro crt in high-risk locally advanced cervical cancer: the keynote-a18 study
-
3:18
#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
-
2:37
#esmo22 highlights on abemaciclib nsai in hr /her2- advanced breast cancer: the monarch 3 study
-
4:58
expert report on neoadjuvant immune checkpoint inhibitors for melanoma
-
2:26
#esmo21 highlights on pembro chemo in 1st-line metastatic cervical cancer: the keynote-826 study
-
0:29
adjuvant treatment for high risk hr breast cancer | esmo 2023 breast cancer highlights
-
33:28
esmo 2022: highlights, commentary and analysis